BGB-3111

Phase 3Small molecule

BeiGene

BGB-3111 is one of 49 small molecule programs targeting Macroglobulinemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MacroglobulinemiaActive, not recruiting

MacroglobulinemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

67 competitors in Macroglobulinemia

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

1 2

Rituxan

Roche

Phase 2

23 3

Leukeran

Akero Therapeutics

Phase 3

1 4

Thalomid

Bristol-Myers Squibb

Phase 2

2 5

Calquence

AstraZeneca

Phase 2

2 6

Darzalex

Johnson & Johnson

Phase 2

2 7

Velcade

SShilpa Grover, MD, MPH

Phase 2

11 8

Jaypirca

Eli Lilly

Phase 2

1 9

Fludara

Sanofi

Phase 2

1 10

Adriamycin

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

TED

NCT06463691

Clinical

Trials by Indication[1]

Cardiac Repolarization1 trial

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

Completed· BeiGene logo

BeiGene·Phase 1·NCT03432884·40 enrolled

Absorption1 trial

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

Completed· BeiGene logo

BeiGene·Phase 1·NCT04163783·6 enrolled

Interaction1 trial

A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects

Completed· BeiGene logo

BeiGene·Phase 1·NCT03561298·18 enrolled

Macroglobulinemia1 trial

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

Completed· BeiGene logo

BeiGene·Phase 3·NCT03053440·201 enrolled

TED1 trial

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06463691·30 enrolled

1 more indication

Phase 11 trial

Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

Completed· BeiGene logo

BeiGene·Phase 1·NCT03301181·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for BGB-3111. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGB-3111 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGB-3111. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeiGene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BeiGene

BGB-3111

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Cardiac Repolarization1 trial

Absorption1 trial

Interaction1 trial

Macroglobulinemia1 trial

TED1 trial

Phase 11 trial

References

Drug Info

Quick Facts

Related News